Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Essum is a Swedish biotechnology company specializing in the research and development of probiotic lactic acid bacteria for human health applications. The company focuses on the therapeutic potential of the microbiome, particularly in dermatology and gastroenterology, utilizing its proprietary strains like Lactobacillus coryniformis LB244. Essum's lead programs target atopic dermatitis and skin barrier function, aiming to provide natural, evidence-based alternatives to traditional pharmacological treatments. Their business model encompasses both internal product development and licensing of their specialized bacterial strains to global partners in the healthcare and skincare industries. The company is a spin-off from Umeå University and maintains a strong foundation in clinical research.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Essum.